EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> Pharming began a phase 1/2 trial of its recombinant human C1 esterase inhibitor in patients with pre-eclampsia. The trial is scheduled to deliver data in the third quarter of 2020. Release 

> Oncurious received a grant from Flanders Innovation and Entrepreneurship to support preclinical development of its cancer immunotherapies. The Belgian biotech hopes to identify and test multispecific biologics. Statement 

> Galapagos and Servier completed enrollment in a phase 2 osteoarthritis trial. The trial is assessing the effect of 52 weeks of treatment with ADAMTS-5 inhibitor GLPG1972. Release 

Sponsored by Clinical Ink

White Paper: Keep Your GI Trials Moving During COVID-19

Clinical Ink’s intimate knowledge of and experience with GI trials enables a better deployment experience and improved trial conduct. Learn how our GI-specific data capture solutions can support virtual and hybrid trials during COVID-19.

> A phase 2b trial of NeRRe Therapeutics’ orvepitant missed its primary endpoint. The neurokinin-1 receptor antagonist was no better than placebo at reducing awake cough frequency in refractory chronic cough. Statement 

> Pfizer picked a clinical candidate from its collaboration with Sosei Heptares, triggering a $3 million (€2.7 million) milestone payment. The candidate is the second picked by Pfizer in as many months. Release

> Immunicum posted phase 1/2 data on its lead candidate in gastrointestinal stromal tumors. Release

Suggested Articles

Dewpoint Therapeutics is teaming up with Merck to develop a new way to fight HIV using its molecular condensates platform.

The study linked SPK-8011 to improvements in factor VIII expression and bleeding out to 3.3 years, but it will be 2021 before phase 3 dosing begins.

Auxolytic's “safety switch” for cell therapy hinges on depriving the cells of the nutrient uridine. The startup has promising results in mouse models.